Fig. 9From: Synthetic carbohydrate-based vaccines: challenges and opportunitiesStructures of (a) PSII synthetic glycoconjugates 50–52 against Clostridium difficile. (b) Native PSII-CRM197 glycoconjugate 53Back to article page